Turkey · Delayed Price · Currency is TRY IST:ORZAX Statistics
Total Valuation
IST:ORZAX has a market cap or net worth of TRY 32.87 billion. The enterprise value is 36.24 billion.
| Market Cap | 32.87B |
| Enterprise Value | 36.24B |
Important Dates
The next estimated earnings date is Thursday, September 24, 2026.
| Earnings Date | Sep 24, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
IST:ORZAX has 338.50 million shares outstanding.
| Current Share Class | 246.40M |
| Shares Outstanding | 338.50M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 31.89% |
| Owned by Institutions (%) | n/a |
| Float | 52.50M |
Valuation Ratios
The trailing PE ratio is 23.64.
| PE Ratio | 23.64 |
| Forward PE | n/a |
| PS Ratio | 4.07 |
| PB Ratio | 9.85 |
| P/TBV Ratio | 10.55 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | 28.74 |
| EV / Sales | 4.49 |
| EV / EBITDA | 12.62 |
| EV / EBIT | 13.68 |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.61, with a Debt / Equity ratio of 1.31.
| Current Ratio | 1.61 |
| Quick Ratio | 1.05 |
| Debt / Equity | 1.31 |
| Debt / EBITDA | 1.53 |
| Debt / FCF | -5.98 |
| Interest Coverage | 2.48 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | n/a |
| Return on Invested Capital (ROIC) | 26.95% |
| Return on Capital Employed (ROCE) | 58.15% |
| Weighted Average Cost of Capital (WACC) | n/a |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | 1,011 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, IST:ORZAX has paid 572.42 million in taxes.
| Income Tax | 572.42M |
| Effective Tax Rate | 31.22% |
Stock Price Statistics
| Beta (5Y) | n/a |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | n/a |
| 200-Day Moving Average | n/a |
| Relative Strength Index (RSI) | 54.48 |
| Average Volume (20 Days) | 20,056,468 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, IST:ORZAX had revenue of TRY 8.07 billion and earned 1.26 billion in profits. Earnings per share was 4.11.
| Revenue | 8.07B |
| Gross Profit | 5.22B |
| Operating Income | 2.65B |
| Pretax Income | 1.83B |
| Net Income | 1.26B |
| EBITDA | 2.82B |
| EBIT | 2.65B |
| Earnings Per Share (EPS) | 4.11 |
Balance Sheet
The company has 1.01 billion in cash and 4.38 billion in debt, with a net cash position of -3.38 billion or -9.97 per share.
| Cash & Cash Equivalents | 1.01B |
| Total Debt | 4.38B |
| Net Cash | -3.38B |
| Net Cash Per Share | -9.97 |
| Equity (Book Value) | 3.34B |
| Book Value Per Share | 10.87 |
| Working Capital | 3.22B |
Cash Flow
In the last 12 months, operating cash flow was -139.03 million and capital expenditures -593.87 million, giving a free cash flow of -732.89 million.
| Operating Cash Flow | -139.03M |
| Capital Expenditures | -593.87M |
| Depreciation & Amortization | 167.83M |
| Net Borrowing | 2.80B |
| Free Cash Flow | -732.89M |
| FCF Per Share | -2.17 |
Margins
Gross margin is 64.70%, with operating and profit margins of 32.83% and 15.63%.
| Gross Margin | 64.70% |
| Operating Margin | 32.83% |
| Pretax Margin | 22.72% |
| Profit Margin | 15.63% |
| EBITDA Margin | 34.91% |
| EBIT Margin | 32.83% |
| FCF Margin | n/a |
Dividends & Yields
IST:ORZAX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | 69.94% |
| Buyback Yield | n/a |
| Shareholder Yield | n/a |
| Earnings Yield | 3.84% |
| FCF Yield | -2.23% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
IST:ORZAX has an Altman Z-Score of 2.39 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.39 |
| Piotroski F-Score | 1 |